Replies to post #155767 on Amarin Corp Plc (AMRN)

[staccani]

I haven't read TTE posts on the issue, but if I consider that on average we had around 47 first events more in the placebo arm vs treated arm each year, and I apply 25% more events each subsequent year to those 47 people added each year, I get around 150 cumulative additioanl events in the placebo arm compared to the V arm, which should bring the RRR of V versus the placebo arm to 36%.
This will not be reflected in the primary endpoint but it should show to some degree into the secondary endpoints. IMO we may see some surprising numbers tomorrow, as the sum of the secondary endpoints RRR should be higher than the primary endpoint RRR and my assumption is that this should be reflected mainly in the CVD Death numbers , as the higher the number of events in the same subject , the higher the chance this would be a fatal event